Risk and safe signaling pathway involvement in apolipoprotein a-i-induced cardioprotection

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kalakech, Hussein ^a   Hibert, Pierre ^a   Prunier Mirebeau, Delphine ^a   Tamareille, Sophie ^a   Letournel, Franck ^a   Macchi, Laurent ^a   Pinet, Florence ^b   Furber, Alain ^a   Prunier, Fabrice ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B; REPERFUSION INJURY SALVAGE KINASE; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDITIS; CELL INFILTRATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME PHOSPHORYLATION; HEART EDEMA; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; RAT; RAT MODEL; REMOTE ISCHEMIC PRECONDITIONING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SURVIVOR ACTIVATING FACTOR ENHANCEMENT SIGNALING PATHWAY; ANIMAL; HEART INFARCTION PREVENTION; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; WISTAR RAT;

ANIMALS; APOLIPOPROTEIN A-I; CARDIOTONIC AGENTS; GLYCOGEN SYNTHASE KINASE 3; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84907222777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107950     Document Type: Article

References (59)

1. Piper HM, Garcia-Dorado D, Ovize M (1998) A fresh look at reperfusion injury. Cardiovasc Res 38: 291-300.
2. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357: 1121-1135.
3. Hausenloy DJ, Yellon DM (2008) Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 79: 377-386.
4. Heusch G, Schulz R (2002) Remote preconditioning. J Mol Cell Cardiol 34: 1279-1281.
5. Saxena P, Newman MA, Shehatha JS, Redington AN, Konstantinov IE (2010) Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg 25: 127-134.
6. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in noncardiac tissue. Circulation 94: 2193-2200.
7. Pell TJ, Baxter GF, Yellon DM, Drew GM (1998) Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. Am J Physiol 275: H1542-1547.
8. Birnbaum Y, Hale SL, Kloner RA (1997) Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 96: 1641-1646.
9. Kharbanda RK, Nielsen TT, Redington AN (2009) Translation of remote ischaemic preconditioning into clinical practice. Lancet 374: 1557-1565.
10. Kloner RA (2009) Clinical application of remote ischemic preconditioning. Circulation 119: 776-778.
11. Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, et al. (2006) Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 47: 2277-2282.
12. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, et al. (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382: 597-604.
13. Hausenloy DJ, Candilio L, Laing C, Kunst G, Pepper J, et al. (2012) Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol 101: 339-348.
14. Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, et al. (2009) Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 119: 820-827.
15. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, et al. (2010) Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727-734.
16. Prunier F, Angoulvant D, Saint Etienne C, Vermes E, Gilard M, et al. (2014) The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. Basic Res Cardiol 109: 400.
17. Shimizu M, Tropak M, Diaz RJ, Suto F, Surendra H, et al. (2009) Transient limb ischaemia remotely preconditions through a humoral mechanism acting directly on the myocardium: evidence suggesting cross-species protection. Clin Sci (Lond) 117: 191-200.
18. Dickson EW, Lorbar M, Porcaro WA, Fenton RA, Reinhardt CP, et al. (1999) Rabbit heart can be "preconditioned" via transfer of coronary effluent. Am J Physiol 277: H2451-2457.
19. Shi W, Vinten-Johansen J (2012) Endogenous cardioprotection by ischaemic postconditioning and remote conditioning. Cardiovasc Res 94: 206-216.
20. Li J, Xuan W, Yan R, Tropak MB, Jean-St-Michel E, et al. (2011) Remote preconditioning provides potent cardioprotection via PI3 K/Akt activation and is associated with nuclear accumulation of beta-catenin. Clin Sci (Lond) 120: 451-462.
21. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croue A, et al. (2011) RISK and SAFE signaling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 106: 1329-1339.
22. Hibert P, Prunier-Mirebeau D, Beseme O, Chwastyniak M, Tamareille S, et al. (2013) Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. PLoS One 8: e77211.
23. Hepponstall M, Ignjatovic V, Binos S, Monagle P, Jones B, et al. (2012) Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans. PLoS One 7: e48284.
24. Linsel-Nitschke P, Tall AR (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4: 193-205.
25. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135.
26. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, et al. (2003) High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 92: 330-337.
27. Imaizumi S, Miura S, Nakamura K, Kiya Y, Uehara Y, et al. (2008) Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol 51: 1604-1612.
28. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, et al. (2006) High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114: 1403-1409.
29. Gu SS, Shi N, Wu MP (2007) The protective effect of Apolipoprotein A-I on myocardial ischemia-reperfusion injury in rats. Life Sci 81: 702-709.
30. Frias MA, James RW, Gerber-Wicht C, Lang U (2009) Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc Res 82: 313-323.
31. Frias MA, Lecour S, James RW, Pedretti S (2012) High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT 1: 92-100.
32. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, et al. (2010) High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 298: H1022-1028.
33. Frias MA, Pedretti S, Hacking D, Somers S, Lacerda L, et al. (2013) HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis 228: 110-116.
34. Shi N, Wu MP (2008) Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats. J Biomed Sci 15: 577-583.
35. Kanoria S, Jalan R, Seifalian AM, Williams R, Davidson BR (2007) Protocols and mechanisms for remote ischemic preconditioning: a novel method for reducing ischemia reperfusion injury. Transplantation 84: 445-458.
36. Veighey K, Macallister RJ (2012) Clinical applications of remote ischemic preconditioning. Cardiol Res Pract 2012: 620681.
37. Schmidt MR, Kristiansen SB, Botker HE (2013) Remote ischemic preconditioning: no loss in clinical translation. Circ Res 113: 1278-1280.
38. Hausenloy DJ, Yellon DM (2011) The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 8: 619-629.
39. Konstantinov IE, Li J, Cheung MM, Shimizu M, Stokoe J, et al. (2005) Remote ischemic preconditioning of the recipient reduces myocardial ischemia-reperfusion injury of the denervated donor heart via a Katp channel-dependent mechanism. Transplantation 79: 1691-1695.
40. Gordon DJ, Rifkind BM (1989) High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321: 1311-1316.
41. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, et al. (2005) High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 26: 890-896.
42. deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211.
43. O'Connell BJ, Genest J Jr (2001) High-density lipoproteins and endothelial function. Circulation 104: 1978-1983.
44. Saemann MD, Poglitsch M, Kopecky C, Haidinger M, Horl WH, et al. (2011) The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest 40: 1131-1143.
45. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, et al. (2004) Antiinflammatory properties of HDL. Circ Res 95: 764-772.
46. Hafiane A, Genest J (2013) HDL, Atherosclerosis, and Emerging Therapies. Cholesterol 2013: 891403.
47. Getz GS, Wool GD, Reardon CA (2010) HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des 16: 3173-3184.
48. Frias MA, Lang U, Gerber-Wicht C, James RW (2010) Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res 85: 118-126.
49. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232.
50. Lacerda L, Somers S, Opie LH, Lecour S (2009) Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84: 201-208.
51. Hausenloy DJ, Lecour S, Yellon DM (2011) Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 14: 893-907.
52. Huffman LC, Koch SE, Butler KL (2008) Coronary effluent from a preconditioned heart activates the JAK-STAT pathway and induces cardiopro-tection in a donor heart. Am J Physiol Heart Circ Physiol 294: H257-262.
53. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, et al. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543-1550.
54. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, et al. (2008) Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 196: 240-247.
55. Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM (2014) High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 114: 171-182.
56. Zhu X, Parks JS (2012) New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 32: 161-182.
57. Shimizu M, Saxena P, Konstantinov IE, Cherepanov V, Cheung MM, et al. (2010) Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res 158: 155-161.
58. Konstantinov IE, Arab S, Kharbanda RK, Li J, Cheung MM, et al. (2004) The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. Physiol Genomics 19: 143-150.
59. Wei M, Xin P, Li S, Tao J, Li Y, et al. (2011) Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res 108: 1220-1225.